Quick Answer
Aprea Therapeutics, Inc. reported Cash and Equivalents of $14.60 million for fiscal year 2025.
Aprea Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $14.60M | -36.1% |
| 2024 | $22.85M | +5.8% |
| 2023 | $21.61M | -24.9% |
| 2022 | $28.79M | -45.8% |
| 2021 | $53.08M | -40.4% |
| 2020 | $89.02M | -31.6% |
| 2019 | $130.09M | +98.1% |
| 2018 | $65.68M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $13.72M | -47.7% | -17.0% |
| June 30, 2025 | $16.53M | -42.4% | -14.2% |
| March 31, 2025 | $19.28M | -40.5% | -15.6% |
| December 31, 2024 | $22.85M | +5.8% | -13.0% |
| September 30, 2024 | $26.25M | +3.5% | -8.5% |
| June 30, 2024 | $28.69M | +3.6% | -11.4% |
| March 31, 2024 | $32.37M | +4.4% | +49.8% |
| December 31, 2023 | $21.61M | -24.9% | -14.8% |
- Aprea Therapeutics, Inc. showed a decrease of -36.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Aprea Therapeutics, Inc.’s cash and equivalents has declined by 77.8% (from $65.68 million to $14.60 million).
- The most recent figure is from Aprea Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: